FDA advisers say Sanofi's MS drug Lemtrada can be approved

11/14/2013 | PharmaTimes (U.K.) · Bloomberg

An FDA advisory committee said Sanofi's Lemtrada, or alemtuzumab, was not so risky that it precluded approval as a treatment for multiple sclerosis. The drug, however, should not be used for first-line treatment, the panel said. The agency is set to issue a decision by Dec. 27.

View Full Article in:

PharmaTimes (U.K.) · Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI